Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers

Adel Alblihy(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Mashael Algethami(University of Nottingham), Anna M. Grabowska(Silesian University of Technology), Juliette Brownlie(University of Nottingham), Ian Hickson(Janssen (United States)), Ahmed Shoqafi(University of Nottingham), Natalie J. Tatum(Cancer Research UK), Paloma Ordóñez‐Morán(University of Nottingham), Jennie N. Jeyapalan(University of Nottingham), Reem Ali(Hamad bin Khalifa University), Michael S. Toss(Nottingham City Hospital), Nigel P. Mongan(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
npj Precision Oncology
July 19, 2022
10.1038/s41698-022-00298-0
Cited by 23

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
|Nature Genetics|2016|439
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374